Treatment strategies for chronic stable angina

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 18, 2011, Pages 2833-2844

  Kaski, Juan Carlos ^a   Arrebola Moreno, Antonio ^a   Dungu, Jason ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anti anginal therapy; Chronic stable angina; Coronary artery disease; Ischaemic heart disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; IVABRADINE; NEVIBOLOL; NICORANDIL; RANOLAZINE; TRIMETAZIDINE; UNCLASSIFIED DRUG;

ANAMNESIS; CORONARY ARTERY DISEASE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; STABLE ANGINA PECTORIS;

ANGINA, STABLE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; CORONARY OCCLUSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL REVASCULARIZATION; OXYGEN CONSUMPTION; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 81855183761     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.634799     Document Type: Review

References (76)

1. Fox K, Garcia MA, Ardissino D, et al. Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG).Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-81
2. Kaski JC. Pathophysiology and management of patients with chest pain and normal arteriograms (cardiac syndrome X).Circulation 2004;109:568-72
3. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:830-40
4. Maseri A, Chierchia S, Kaski JC. Mixed angina pectoris. Am J Cardiol 1985;56:30E-3E
5. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-5
6. Maseri A, Davies G, Hackett D, et al. Coronary artery spasm and vasoconstriction. The case for a distinction. Circulation 1990;81:1983-91
7. Crea F, Lanza GA. Angina pectoris and normal coronary arteries: cardiac syndrome X. Heart 2004;90:457-63
8. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004;15:1983-92
9. Pepine CJ, Nichols WW. The pathophysiology of chronic ischemic heart disease. Clin Cardiol 2007;30(Suppl I):4-9
10. Arant CB, Wessel TR, Olson MB, et al. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain: results from the National Heart, Lung, and Blood Institute Women's Ischemia Syndrome Evaluation Study. J Am Coll Cardiol 2004;43:2009-14
11. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003;108:1772-8
12. Hale SL, Shryock JC, Belardinelli L, et al. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 2008;44:954-67
13. Bers DM, Barry WH, Despa D. Intracellular Na+ regulation in cardiac myocytes. Cardiovasc Res 2003;57:897-912
14. Eigel BN, Hadley RW. Contribution of the Na+ channel and Na+/H+ exchanger to the anoxic rise of [Na+] in ventricular myocytes. Am J Physiol Heart Circ Physiol 1999;46:H1817-22
15. Silverman HS, Stern MD. Ionic basis of ischaemic cardiac injury: insights from cellular studies. Cardiovasc Res 1994;28:581-97
16. Kane G, Liu X, Yamada S, et al. Cardiac KATP channels in health and disease. J Mol Cell Cardiol 2005;38:937-43
17. Hibino H, Inanobe A, Furutani et al. Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev 2010;90:291-366
18. Fraker TD Jr, Fihn SD; on behalf of 2002 Chronic Stable Angina Writing Committee; American College of Cardiology; American Heart Association. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007;50:2264-74
19. Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90:2645-57
20. Daly CA, De Stavola B, Lopez-Sendon J, et al. EuroHeart Survey Investigators. Predicting prognosis in stable angina - results from the EuroHeart Survey of stable angina: prospective observational study. BMJ 2006;332:262-7
21. Omland T. B-type natriuretic peptides: prognostic markers in stable coronary artery disease. Expert Rev Mol Diagn 2008;8:217-25
22. Bartecchi CE, MacKenzie TD, et al. The human costs of tobacco use. N Engl J Med 1994;330:907-12
23. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts).Eur J Cardiovasc Prev Rehabil 2003;10:S1-10
24. Tuttle KR, Shuler LA, Packard DP, et al. Comparison of low-fat versus Mediterranean-style dietary intervention after first myocardial infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial).Am J Cardiol 2008;101:1523-30
25. . Zhang F, Wu SZ, Zhang L, et al. Effects of simvastatin on plasma SOD. MDA and 8-iso-PGF2alpha in patients with stable angina. Nan Fang Yi Ke Da Xue Xue Bao 2010;30:2646-8
26. He K, Song Y, Daviglus ML, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 2004;109:2705-11
27. Di Castelnuovo A, Rotondo S, Iacoviello L, et al. Meta-analysis of wineand beer consumption in relation to vascular risk. Circulation 2002;105:2836-44
28. Graham I, Atar D, Borch-Johnsen K, et al. European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG).European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).Eur Heart J 2007;28:2375-414
29. Schunkert H, Hense HW, Brockel U, et al. Differential effects of antihypertensive drugs on neurohormonal activation: insights from a population-based sample. J Intern Med 1998;244:109-19
30. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988;260:2088-93
31. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST).Circulation 1994;90:762-8
32. Shu DF, Dong BR, Lin XF, et al. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil 2011; [Epub ahead of print]
33. Kamp O, Metra M, Bugatti S, et al. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs 2010;70:41-56
34. Pronko TP, Zinchuk VV. Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertension. Clin Physiol Funct Imaging 2009;29:170-6
35. Flather MD, Shibata MC, Coats AJ, et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).Eur Heart J 2005;26:215-25
36. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35
37. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999;281:1927-36
38. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet 2004;364:849-57
39. Nossaman VE, Nossaman BD, Kadowitz PJ. Nitrates and nitrites in the treatment of ischemic cardiac disease. Cardiol Rev 2010;18:190-7
40. Munzel T. Recent findings on nitrates: their action, bioactivation and development of tolerance. Dtsch Med Wochenschr 2008;133:2277-82
41. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug Trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3- ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-8
42. Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in Angina Combination Therapy-the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005;12:35-42
43. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Rev 2006;53:399-406
44. Tardif J-C, Ford I, Tendera M, et al. INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-36
45. Borer JS, Tardif JC. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus. Am J Cardiol 2010;105:29-35
46. Fox K, Ford I, Steg PG, et al. BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-16
47. Swedberg K, Komajda M, Bohm M, et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet 2010;376:875-85
48. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269-75
49. Chaitman BR, Skettino SL, Parker JO, et al. Antiischemic effects and long-term survival during Ranolazine monotherapy in patients with chronic severe angina.J Am Coll Cardiol 2004;43:1375-82
50. Chaitman BR, Pepine CJ, Parker JO, et al. Combination assessment of ranolazine in stable angina (CARISA) investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomised controlled trial. JAMA 2004;291:309-16
51. Stone PH, Gratsiansky NA, Blokhin A, et al. ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J Am Coll Cardiol 2006;48:566-75
52. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non ST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-52
53. Morrow DA, Scirica BM, Chaitman BR, et al. MERLIN-TIMI 36 Investigators. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in theMERLIN-TIMI 36 randomized controlled trial. Circulation 2009;119:2032-9
54. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
55. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
56. Ciulla MM, Paliotti R, Esposito A, et al. Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalapril. J Hypertens 2009;27:626-32
57. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).Lancet 1996;348:1329-39
58. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
59. Skogastierna C, Luksha L, Kublickiene K, et al. Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide. Heart Vessels 2011 Jan 7. [Epub ahead of print]
60. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation. American Heart Association implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
61. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
62. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22
63. Hlatky MA. Expanding the orbit of primary prevention - moving beyond JUPITER. N Engl J Med 2008;359:2280-2
64. Chhatriwalla AK, Nicholls SJ, Nissen SE. The ASTEROID trial: coronary plaque regression with high-dose statin therapy. Future Cardiol 2006;2:651-4
65. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).European Association for Percutaneous Cardiovascular Interventions. Eur Heart J 2010;31:2501-55
66. Pfisterer ME, Zellweger MJ, Gersh BJ. Management of stable coronary artery disease. Lancet 2010;375:763-72
67. Jeremias A, Kaul S, Rosengart TK, et al. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med 2009;122:152-61
68. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16
69. Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979;59:421-30
70. Frye RL, August P, Brooks MM, et al. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-15
71. Serruys PW, Morice MC, Kappetein AP. et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360(10):961-72
72. Magro M, Nauta S, Simsek C, et al. Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: the MI SYNTAXscore study. Am Heart J 2011;161:771-81
73. Johnston N, Schenck-Gustafsson K, Lagerqvist B. Are we using cardiovascular medications and coronary angiography appropriately in men and women with chest pain? Eur Heart J 2011;32:1331-6
74. Bugiardini R, Yan AT, Yan RT, et al. Factors influencing underutilization of evidence-based therapies in women. Eur Heart J 2011;32:1331-6
75. Shaw LJ, Bugiardini R, Merz CN. Women and ischaemic heart disease: evolving knowledge. J Am Coll Cardiol 2009;54:1561-75
76. Ciambrone G, Kaski JC. Gender differences in the treatment of chronic ischemic heart disease: prognostic implications. Fundam Clin Pharmacol 2010;24:707-10